Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07276386CT.gov Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma | — | Recruiting | — | — | — |
NCT06070012CT.gov Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | — | Recruiting | — | — | — |
NCT07057596CT.gov Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma | — | Recruiting | — | — | — |
NCT06627244CT.gov Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | — | Recruiting | — | — | — |
NCT06246149CT.gov Adjuvant Tebentafusp in High Risk Ocular Melanoma | — | Recruiting | — | — | — |
NCT05315258CT.gov Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma | — | Active Not Recruiting | — | — | — |
NCT03070392CT.gov Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | — | Completed | — | — | — |
NCT02570308CT.gov A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | — | Completed | — | — | — |
NCT04960891CT.gov A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tebentafusp (this asset) | H. Lee Moffitt Cancer Center and Research Institute | P3 | BB · 66 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for Tebentafusp
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | BB · 70 |
| Cutaneous Melanoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tebentafusp in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tebentafusp-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →